SMS Pharma. Q1 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- Ibuprofen is a flagship product with recent CEP approval, enabling sales in European markets and expected to generate good revenues going forward.
- Targeting 30-35% growth in Ibuprofen contribution.
- Plans to add 8 to 10 new products to the portfolio in the next year to increase non-ARV product revenue share.
- Sitagliptin launch is recent; Indian market estimated around 150+ tons, offering significant opportunity.
- The company is focused on expanding market share domestically and internationally, especially for newly launched products.
- ARV product Tenofovir contributes around 35% of revenue; sales depend on tender outcomes with some growth potential.
- Joint Venture (JV) products could contribute 20-25% of revenue, up from around 15%.
- Overall, non-ARV products are positioned for significant growth to diversify revenue and reduce dependence on ARV APIs.
- FY23 is expected to see improved capacity utilization and sales volumes, with EBITDA and PAT positive turnaround targeted.
See what SMS Pharma. management said on margin guidance — free account, 30 seconds.
Fundraise plans
- The transcript does not mention any current or planned fundraising through debt or equity.
- There is no discussion of any capital raising activities in the Q1 FY23 earnings call held on August 18, 2022.
- The management focuses on commercial expansion, product launches, and improving profitability without mentioning any new funding rounds.
- Capex and R&D investments are being managed internally without indication of external fundraising.
- Hence, based on available information, no new debt or equity fundraising is planned or announced as of this call.
See what SMS Pharma. management said on order book — free account, 30 seconds.
Capex plans
Yes- No explicit mention of new or upcoming CAPEX or capital investments in the transcript.
- CFO Vamsi Krishna Potluri noted that depreciation remained nominal in FY23, as major capitalization happened in FY22, indicating limited new CAPEX in the current fiscal year.
- The company is focusing on commercializing new products (e.g., Sitagliptin, Ibuprofen) and expanding R&D (planned growth of 20% in R&D spend in FY23).
- Emphasis placed on strategic investments in product launches, geographic expansion, and customer addition rather than heavy capital expenditure.
- Inventory build-up was noted for launching Sitagliptin and COVID-related drugs, but raw material purchases and major CAPEX are under control.
- Overall, strategic focus is on operational expansion rather than announced large-scale capital investments at this time.
Track SMS Pharma. — get its next earnings analysis in your feed
Margin guidance
Category 3- The company is optimistic about turning EBITDA positive by end of Q2 FY23 and PAT positive by end of FY23 (Page 12).
- Strong focus on commercializing Ibuprofen in Europe after CEP approval, targeting significant revenue growth (Pages 6, 13).
- Ibuprofen revenue contribution could grow to 35-40% of the top line by FY23-24 (Page 6).
- Growth expected from newly launched products such as Sitagliptin with an India market size assumption of around 150 tons and targeting good market share (Pages 14-15).
- ARV product Tenofovir sales remain uncertain due to tender dependencies; company working to diversify product mix to reduce dependence on ARV (Pages 12, 15).
- Launches from JV expected to contribute 20-25% of revenue, with focus on new products post-patent expiry (Page 8).
- R&D expenses expected to increase by about 20% in FY23, supporting new product launches (Page 4).
- Overall, the company is confident of overcoming short-term challenges and plans steady revenue and profitability growth through new product launches, customer additions, and geographical expansion (Pages 3-4).
Order book
- The company is currently facing difficulty in predicting orderbook due to delays and uncertainty in government tenders, especially in the ARV segment.
- Clarity on ARV orders and tender outcomes is expected by the next quarter.
- Inventory buildup (approx. ₹275 crore) is partly due to readiness for product launches like Sitagliptin and Molnupiravir.
- The company is actively pushing partners for demand forecasts and contract manufacturing projections.
- Ibuprofen and other products are gaining traction, with aims to increase capacity utilization from 22% in Q1 to 70-80% by Q4 FY23.
- New product launches (including Sitagliptin in India) provide significant revenue potential and order flow opportunities.
- The business is focused on diversifying revenue streams beyond ARV products and expanding into domestic and international markets.
How does SMS Pharma. rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does SMS Pharma. rank in Pharmaceuticals & Biotechnology?
Compare SMS Pharma. against every Pharmaceuticals & Biotechnology company (Q1 FY23) on revenue, margins and earnings-call signals.
Continue your research
What SMS Pharma.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…